ArticleInternational journal of clinical and experimental medicine2015
Interaction between peroxisome proliferator- activated receptor gamma polymorphism and overweight on diabetic retinopathy in a Chinese case-control study.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Association betweenAging · 2021Pooled it
- Precision Medicine for Diabetic Retinopathy: Integrating Genetics, Biomarkers, Lifestyle, and AI.Genes · 2025Review
- Evaluating lipid-lowering drug targets for full-course diabetic retinopathy.The British journal of ophthalmology · 2025Article
- 2,2',4,4',5,5'-Hexabromophenyl ether (BDE-153) causes abnormal insulin secretion and disorders of glucose and lipid metabolism in mice.Journal of the Chinese Medical Association : JCMA · 2023Article
- Association of Peroxisome Proliferator-Activated Receptors (PPARs) with Diabetic Retinopathy in Human and Animal Models: Analysis of the Literature and Genome Browsers.PPAR research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeroxisome proliferator-activated receptors γ (PPAR γ) and overweight were both associated with diabetic retinopathy (DR), so the aim of this study was to investigate the association of four single nucleotide polymorphisms (SNPs) of PPAR γ with DR and additional role of gene-BMI interaction.
methodsA total of 500 patients with T2DM (236 men, 264 women), with a mean age of 54.3 ± 15.8 years old, were selected, including 247 diabetic retinopathy patients and 253 controls. Four SNPs were selected for genotyping in the case-control study: rs1805192, rs709158, rs3856806, rs4684847. Logistic regression model was used to examine the interaction between SNP and overweight on DR, odds ratio (OR) and 95% confident interval (95% CI) were calculated.
resultsThe carriers of C allele of the rs1805192 polymorphism revealed decreased DR risk than those with Pro/Pro variants (Pro/Ala+Ala/Ala versus Pro/Pro, adjusted OR (95% CI)=0.86 (0.65-0.96), P=0.012), after adjusting for covariates. We also found that obese subjects with Pro/Ala or Ala/Ala variants genotype have lowest DR risk, compared to obese subjects with Pro/Pro genotype or non- obese subjects with Pro/Ala or Ala/Ala (OR=0.40, 95% CI=0.32-0.63), after covariates adjustment.
conclusionsOur results support an important association between rs1805192 minor allele (Ala allele) of PPAR γ and DR, the interaction analysis shown a combined effect of Ala- BMI interaction on DR.
Indexed as
Identifiers
26885119PMC4723964W2278081824What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.